Skip to content
Open access · CC-BY via OpenAlex

Proteomics assisted improvement prediction of risk for adverse cardiovascular events in individuals with metabolic syndrome

Yanlin Chen, Wei Pan, Haichu Wen, Yifan Wang, Jifang Zhang, Bokang Qiao, 贾利新, Jie Du

BMC Cardiovascular Disorders · 2026

Abstract

BACKGROUND: Traditional clinical models, designed for the general population, are insufficient for capturing the complex molecular pathology that drives major adverse cardiovascular events (MACEs) in individuals with metabolic syndrome (MetS). This study aimed to leverage large-scale proteomics to improve risk stratification in MetS and to investigate the potential causal effects of identified proteins using Mendelian Randomization (MR). METHODS: We analyzed 2,911 plasma proteins in 12,308 MetS participants from the UK Biobank. A protein prediction model was constructed using the least absolute shrinkage and selection operator method to select MACE-associated proteins in the training set. The model's predictive performance was evaluated in a validation set and compared to the clinical PREVENT model. To investigate whether these identified proteins have a causal relationship with MACE, we utilized cis-pQTLs as genetic instruments to perform a two-sample MR analysis. RESULTS: Over a median 14-year follow-up, 1,899 incident MACEs occurred. In the validation set, the protein model significantly outperformed the clinical PREVENT model (C-statistic: 0.730 vs. 0.673, P = 0.003). Crucially, among individuals classified as intermediate-risk by the PREVENT model, the protein score achieved a total net reclassification index of 0.44, driven by the correct reclassification of 64% of individuals who developed MACE. Time-dependent analysis revealed exceptional predictive accuracy for short-term heart failure risk (3-year AUC = 0.90), which was superior to long-term predictions. MR analysis against individual MACE components identified four proteins with causal evidence: genetically higher AGER (soluble RAGE) was associated with lower heart failure risk, and higher MMP-12 with lower stroke risk, whereas higher VAMP5 and NCAN were associated with increased coronary heart disease risk. CONCLUSION: A proteomics-derived model deconstructs the molecular heterogeneity of MACEs risk in individuals with MetS, significantly improving conventional models. Furthermore, integrating MR analysis distinguishes causal drivers from biomarkers, providing novel molecular insights to guide personalized prevention.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1186/s12872-026-06367-7
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Chen, Y., Pan, W., Wen, H., Wang, Y., Zhang, J., Qiao, B., 贾利新, &amp; Du, J. (2026). Proteomics assisted improvement prediction of risk for adverse cardiovascular events in individuals with metabolic syndrome. <em>BMC Cardiovascular Disorders</em>. https://doi.org/10.1186/s12872-026-06367-7
Vancouver
Chen Y, Pan W, Wen H, Wang Y, Zhang J, Qiao B, et al. Proteomics assisted improvement prediction of risk for adverse cardiovascular events in individuals with metabolic syndrome. BMC Cardiovascular Disorders. 2026. doi:10.1186/s12872-026-06367-7.
BibTeX
@article{yanlin2026Proteo, title = {Proteomics assisted improvement prediction of risk for adverse cardiovascular events in individuals with metabolic syndrome}, author = {Yanlin Chen and Wei Pan and Haichu Wen and Yifan Wang and Jifang Zhang and Bokang Qiao and 贾利新 and Jie Du}, journal = {BMC Cardiovascular Disorders}, year = {2026}, doi = {10.1186/s12872-026-06367-7}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings